» Articles » PMID: 38258039

Praziquantel Fifty Years On: A Comprehensive Overview of Its Solid State

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Jan 23
PMID 38258039
Authors
Affiliations
Soon will be listed here.
Abstract

This review discusses the entire progress made on the anthelmintic drug praziquantel, focusing on the solid state and, therefore, on anhydrous crystalline polymorphs, amorphous forms, and multicomponent systems (i.e., hydrates, solvates, and cocrystals). Despite having been extensively studied over the last 50 years, new polymorphs and the greater part of their cocrystals have only been identified in the past decade. Progress in crystal engineering science (e.g., the use of mechanochemistry as a solid form screening tool and more strategic structure-based methods), along with the development of analytical techniques, including Synchrotron X-ray analyses, spectroscopy, and microscopy, have furthered the identification of unknown crystal structures of the drug. Also, computational modeling has significantly contributed to the prediction and design of new cocrystals by considering structural conformations and interactions energy. Whilst the insights on praziquantel polymorphs discussed in the present review will give a significant contribution to controlling their formation during manufacturing and drug formulation, the detailed multicomponent forms will help in designing and implementing future praziquantel-based functional materials. The latter will hopefully overcome praziquantel's numerous drawbacks and exploit its potential in the field of neglected tropical diseases.

Citing Articles

-Schistosomal activity and ADMET properties of 1,2,5-oxadiazinane-containing compound synthesized by visible-light photoredox catalysis.

Itoh K, Nakahara H, Takashino A, Hara A, Katsuno A, Abe Y RSC Med Chem. 2024; .

PMID: 39399310 PMC: 11467761. DOI: 10.1039/d4md00599f.

References
1.
Partridge G, Rao S, Woolley L, Pilmer L, Lymbery A, Prestidge C . Bioavailability and palatability of praziquantel incorporated into solid-lipid nanoparticles fed to yellowtail kingfish Seriola lalandi. Comp Biochem Physiol C Toxicol Pharmacol. 2018; 218:14-20. DOI: 10.1016/j.cbpc.2018.12.007. View

2.
Liu Y, Wang X, Wang J, Ching C . Structural characterization and enantioseparation of the chiral compound praziquantel. J Pharm Sci. 2004; 93(12):3039-46. DOI: 10.1002/jps.20211. View

3.
Lombardo F, Perissutti B, Keiser J . Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model. Eur J Pharm Biopharm. 2019; 142:240-246. DOI: 10.1016/j.ejpb.2019.06.029. View

4.
Lindenberg M, Kopp S, Dressman J . Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004; 58(2):265-78. DOI: 10.1016/j.ejpb.2004.03.001. View

5.
Becket G, Schep L, Tan M . Improvement of the in vitro dissolution of praziquantel by complexation with alpha-, beta- and gamma-cyclodextrins. Int J Pharm. 1999; 179(1):65-71. DOI: 10.1016/s0378-5173(98)00382-2. View